Head-to-head · WeighScore
Harbor vs Live Vital
By GLP-1 ScorecardUpdated
Score comparison
Harbor has the higher recorded score — 72/100 to 62.7/100.
Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.
Before you choose
Before comparing the headline prices, the Harbor review and the Live Vital review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Harbor vs Medro and Live Vital vs Revel RX compare each of them with another graded program, and the list of alternatives to Harbor ranks the programs closest to Harbor on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Harbor | Live Vital |
|---|---|---|
| WeighScore | 72/100 | 62.7/100 |
| Grade | C | C |
| Site position | #94 | #233 |
| Semaglutide | $99/mo (starting dose, compounded) | From $93/mo (annual plan only; enrollment marked coming soon, compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | From $179/mo (annual plan only; monthly price not published, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
What to consider
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Site position #233 · C
Strengths
- Names its medical director
- Uses a licensed 503A pharmacy and serves all 50 states
- Phone and text support numbers are published
What to consider
- The low prices require an annual plan, and no month-to-month price is published
- The FAQ quotes $95 to $200 a month on 10-week or two-month billing, which does not match the plan prices
- Semaglutide is not yet open for enrollment
- Unfinished editorial notes about the pharmacy and payment timing were visible on its own about and refund pages
Featured provider
Live Vital
Live Vital scores 62.7/100 (C). Live Vital is a Utah telehealth company enrolling patients for compounded tirzepatide from $179 a month on an annual plan, with semaglutide listed as coming soon.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.